Legend Biotech Corporation (NASDAQ: LEGN) is a top biotech stock with high potential. TD Cowen analyst Yaron Werber reiterated a Buy rating with a $62.00 price target on October 3. The company faces supply constraints with Carvykti but plans capacity expansions to reach a $1.9 billion sales target by 2025.

Legend Biotech Corporation develops novel therapies for oncology and other indications. While LEGN shows promise as an investment, some believe certain AI stocks offer greater upside potential and less downside risk. Investors can explore an undervalued AI stock benefiting from Trump-era tariffs and the onshoring trend.

Analyst Yaron Werber supports Legend Biotech Corporation’s optimistic future growth potential. The company is confident in overcoming supply constraints by 2025 through planned capacity expansions. LEGN operates in the US, China, and other geographical segments, focusing on advanced cell therapies.

Read more at Yahoo Finance: TD Cowen Reiterates a Buy Rating on Legend Biotech Corporation (LEGN)